Currently, there are 101.75M common shares owned by the public and among those 77.75M shares have been available to trade.
The company’s stock has a 5-day price change of -3.26% and -57.76% over the past three months. DYN shares are trading -41.98% year to date (YTD), with the 12-month market performance down to -19.40% lower. It has a 12-month low price of $13.44 and touched a high of $47.45 over the same period. DYN has an average intraday trading volume of 1.38 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -27.56%, -44.04%, and -57.02% respectively.
Institutional ownership of Dyne Therapeutics Inc (NASDAQ: DYN) shares accounts for 86.77% of the company’s 101.75M shares outstanding.
It has a market capitalization of $1.39B and a beta (3y monthly) value of 1.06. The earnings-per-share (ttm) stands at -$3.56. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.08% over the week and 7.45% over the month.
Earnings per share for the fiscal year are expected to increase by 12.26%, and -8.36% over the next financial year. EPS should grow at an annualized rate of 1.02% over the next five years, compared to -106.26% over the past 5-year period.
Looking at the support for the DYN, a number of firms have released research notes about the stock. Robert W. Baird stated their Outperform rating for the stock in a research note on December 13, 2024, with the firm’s price target at $46. RBC Capital Mkts coverage for the Dyne Therapeutics Inc (DYN) stock in a research note released on November 26, 2024 offered a Outperform rating with a price target of $45. JP Morgan was of a view on October 24, 2024 that the stock is Neutral, while Chardan Capital Markets gave the stock Buy rating on May 21, 2024, issuing a price target of $31- $42. Morgan Stanley on their part issued Overweight rating on April 30, 2024.
